[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
January 8, 1927


JAMA. 1927;88(2):103-104. doi:10.1001/jama.1927.02680280033015

Students of the cancer problem have been observing with interest the reports emanating from Liverpool concerning the value of lead preparations in the treatment of inoperable cancer. At a recent meeting of the British Medical Association, a full summary of the results to date was presented.1 The clinical survey indicates that there is promise of therapeutic benefit in a few selected cases of otherwise hopeless cancer.

The preliminary task before treatment can be begun is the selection of patients who may possibly obtain benefit. Those with operable tumors or growths which have been shown to yield easily to irradiation should be excluded. All those with active renal or cardiac lesions, advanced cachexia, cerebral metastasis or large irremovable tumors must be rejected. Probably those with lung and liver metastasis will ultimately be found not to be benefited, and this group may also have to be removed from the category of